We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+38.9%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$8.13B
AUM Growth
+$1.33B
Cap. Flow
+$252M
Cap. Flow %
3.09%
Top 10 Hldgs %
38.33%
Holding
153
New
32
Increased
35
Reduced
44
Closed
13

Top Buys

Rank Stock Value
1
AGN
Allergan Inc
AGN
+$182M
2
ISRG icon
Intuitive Surgical
ISRG
+$111M
3
ESRX
Express Scripts Holding Company
ESRX
+$60.7M
4
ABBV icon
AbbVie
ABBV
+$52.2M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$48.2M

Top Sells

Rank Stock Value
1
AET
Aetna Inc
AET
+$78.6M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$61.6M
3
CELG
Celgene Corp
CELG
+$61.1M
4
INCY icon
Incyte
INCY
+$58.6M
5
UNH icon
UnitedHealth
UNH
+$51.9M

Sector Composition

Rank Sector Weight
1 Healthcare 83.16%
2 Technology 0.09%
3 Financials 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGN
26
DELISTED
Allergan plc
AGN
$102M 1.25%
495,000
-218,000
-31% -$43.2M
BMRN icon
27
BioMarin Pharmaceuticals
BMRN
$12B
$102M 1.25%
1,493,000
+78,900
+6% +$5.81M
PODD icon
28
Insulet
PODD
$11.7B
$91.7M 1.13%
1,933,500
-955,000
-33% -$42.2M
NBIX icon
29
Neurocrine Biosciences
NBIX
$18.2B
$87.8M 1.08%
5,451,000
+2,820,000
+107% +$48.2M
SHPG
30
DELISTED
Shire pic
SHPG
$87.2M 1.07%
587,000
-137,000
-19% -$21.1M
HNT
31
DELISTED
HEALTH NET INC
HNT
$87.1M 1.07%
2,560,000
+998,600
+64% +$32.8M
MOH icon
32
Molina Healthcare
MOH
$10.6B
$84.6M 1.04%
2,253,000
+189,900
+9% +$7M
CFN
33
DELISTED
CAREFUSION CORPORATION
CFN
$80.9M 1%
2,012,000
-159,500
-7% -$6.45M
STJ
34
DELISTED
St Jude Medical
STJ
$75M 0.92%
1,146,600
+313,000
+38% +$20.4M
SPY icon
35
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$778B
$74.8M 0.92%
400,000
+150,000
+60% +$27.5M
PRTA icon
36
Prothena Corp
PRTA
$444M
$72.4M 0.89%
1,889,000
+687,000
+57% +$22.1M
ZBH icon
37
Zimmer Biomet
ZBH
$18.7B
$67.7M 0.83%
737,686
-122,570
-14% -$11.3M
XLRN
38
DELISTED
Acceleron Pharma
XLRN
$64.4M 0.79%
1,867,800
-249,848
-12% -$11.3M
ARWR icon
39
Arrowhead Research
ARWR
$12.2B
$64.2M 0.79%
3,910,000
+1,781,100
+84% +$31.3M
LAB icon
40
Standard BioTools
LAB
$318M
$63.8M 0.78%
1,447,200
+1,192
+0.1% +$52.4K
JNJ icon
41
Johnson & Johnson
JNJ
$644B
$58.6M 0.72%
597,000
-29,000
-5% -$2.69M
INFI
42
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$56.3M 0.69%
4,736,900
-57,400
-1% -$770K
SYK icon
43
Stryker
SYK
$134B
$51.1M 0.63%
626,700
-90,000
-13% -$7.16M
AFFX
44
DELISTED
Affymetrix Inc
AFFX
$47.7M 0.59%
6,693,000
-117,000
-2% -$943K
OSUR icon
45
OraSure Technologies
OSUR
$276M
$42.8M 0.53%
5,372,000
+384,000
+8% +$2.68M
CLDX icon
46
Celldex Therapeutics
CLDX
$2.82B
$41.5M 0.51%
156,507
+69,134
+79% +$26.5M
ALXN
47
DELISTED
Alexion Pharmaceuticals
ALXN
$40.6M 0.5%
267,000
+34,100
+15% +$5.42M
BMY icon
48
CALL
Bristol-Myers Squibb
BMY
$130B
$39M 0.48%
750,000
+200,000
+36% +$10.6M
LLY icon
49
Eli Lilly
LLY
$1.09T
$32M 0.39%
+543,000
New +$30.3M
TRNX
50
DELISTED
TORNIER N V SHARES (NLD)
TRNX
$31.3M 0.38%
+1,475,100
New +$28.6M
1
2
3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q1 2014 Portfolio in Review

As of Q1 2014, OrbiMed held 153 positions worth $8.13B, up 20% from $6.8B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

OrbiMed deployed $252M of net new capital in Q1 2014, opening 32 new positions and adding to 35 existing holdings. Its largest new stake was Eli Lilly: 543,000 shares worth $32M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 84% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was Aetna Inc, an estimated $78.6M trimmed.

  • OrbiMed's largest Q1 2014 buy was Eli Lilly: 543,000 shares worth $32M.
  • OrbiMed added most to Allergan Inc in Q1 2014, an estimated $182M increase.
  • OrbiMed's biggest Q1 2014 reduction was Aetna Inc, cutting an estimated $78.6M.
  • OrbiMed fully exited QIAGEN NV in Q1 2014, selling an estimated $45.9M.
  • OrbiMed's ten largest holdings make up 38% of its $8.13B portfolio in Q1 2014.
  • OrbiMed opened 32 new positions and closed 13 in Q1 2014.
  • OrbiMed's portfolio value rose 20% quarter-over-quarter to $8.13B.

Based on OrbiMed's 13F filing for Q1 2014, filed 15 May 2014.